Lumason

Serious warning

The strongest warning the FDA requires. It is printed in a box at the top of the label.

Quoted from the official label, section “Boxed Warning”.

Do not take it if

Quoted from the official label, section “Contraindications”.

How to take it

These directions are for this exact strength and form. Another one is different.

• Avoid intra-arterial injection ( 2.1 , 5.3 ) See Full Prescribing Information for reconstitution instructions ( 2.3 ) For intravenous injection :
• Echocardiography in
• adults:
• After reconstitution, administer 2 mL as an intravenous injection ( 2.2 , 2.4 ) Echocardiography in pediatric patients:
• After reconstitution, administer 0.03 mL per kg as an intravenous injection up to a maximum of 2 mL per injection ( 2.2 , 2.4 ) Ultrasonography of the liver in
• adults:
• After reconstitution, administer 2.4 mL as an intravenous injection ( 2.2 , 2.4 ) Ultrasonography of the liver in pediatric patients:
• After reconstitution, administer 0.03 mL per kg as an intravenous injection, up to a maximum of 2.4 mL per injection ( 2.2 , 2.4 ) May repeat dose one time during a single examination ( 2.2 , 2.4 ) Follow each injection with an intravenous flush of 0.9% Sodium Chloride Injection, USP ( 2.2 , 2.4 ) For intravesical administration in pediatric patients :
• Ultrasonography of the urinary tract:
• After reconstitution, administer 1 mL via sterile 6 to 8F urinary catheter.
• Bladder should be first emptied and then partially filled with 0.9% Sodium Chloride Injection, USP before injection of Lumason ( 2.2 , 2.4 ) After Lumason administration, continue filling the bladder with 0.9% Sodium Chloride Injection, USP until the patient has the urge to micturate or at the first sign of back pressure to the infusion ( 2.4 )
• 2.1 Important Administration Instructions Do not administer Lumason by intra-arterial injection [see Warnings and Precautions ( 5.3 )] .
• Recommended Dosage Echocardiography
• Adults The recommended dose of Lumason after reconstitution is 2 mL administered as an intravenous bolus injection during echocardiography.
• During a single examination, a second injection of 2 mL may be administered to prolong contrast enhancement.
• Follow each Lumason injection with an intravenous flush using 5 mL of 0.9% Sodium Chloride Injection, USP.
• Pediatric Patients The recommended dose of Lumason after reconstitution in pediatric patients is 0.03 mL per kg administered as an intravenous injection during echocardiography.
• During a single examination, a second injection of 0.03 mL per kg may be administered, if needed.
• Do not exceed 2 mL per injection.
• Follow Lumason injection with an intravenous flush using 5 mL of 0.9% Sodium Chloride Injection, USP.
• Ultrasonography of the Liver
• Adults The recommended dose of Lumason after reconstitution in adult patients is 2.4 mL administered as an intravenous injection during ultrasonography of the liver.
• During a single examination, a second injection of 2.4 mL may be administered, if needed.
• Follow Lumason injection with an intravenous flush using 5 mL of 0.9% Sodium Chloride Injection, USP.
• Pediatric Patients The recommended dose of Lumason after reconstitution in pediatric patients is 0.03 mL per kg administered as an intravenous injection during ultrasonography of the liver.
• During a single examination, a second injection of 0.03 mL per kg may be administered, if needed.
• Do not exceed 2.4 mL per injection.
• Follow Lumason injection with an intravenous flush of 0.9% Sodium Chloride Injection, USP.
• Ultrasonography of the Urinary Tract Pediatric Patients The recommended dose of Lumason after reconstitution is 1 mL.
• The bladder may be refilled with 0.9% Sodium Chloride Injection, USP for a second cycle of voiding and imaging, without the need of a second Lumason administration.
• 2.3 Reconstitution Instructions Refer to Section 2.3.1 for instructions for using the single patient use kit with diluent provided Refer to Section 2.3.2 for instructions for using the 20-vial pack without diluent provided 2.3.1 Lumason Kit (single patient use kit) Contents of Lumason Kit Inspect the Lumason kit and its components for signs of damage.
• Do not use the kit if the protective caps on the Lumason vial and prefilled syringe with 5 mL 0.9% Sodium Chloride Injection, USP are not intact or if the kit shows other signs of damage.
• Under aseptic conditions, reconstitute the Lumason vial using the following illustrated steps:
• 1.
• Connect the plunger rod to the prefilled 0.9% Sodium Chloride Injection, USP syringe barrel by screwing it clockwise into the syringe (see Figure 1). 2.
• Open the Mini-Spike blister and remove the syringe tip cap (see Figure 2). 3.
• Remove the Mini-Spike green cap and connect the syringe to the Mini-Spike by screwing it in clockwise (see Figure 3). 4.
• Remove the Mini-Spike spike protection and position the spike in the center of the rubber stopper of the vial.
• Press firmly inward until the spike is fully inserted in the stopper (see Figure 4). 5.
• Empty the content of the syringe into the vial by pushing on the plunger rod (see Figure 5). 6.
• Shake vigorously for 20 seconds, mixing all the contents in the vial (see Figure 6).
• A homogeneous white milky liquid indicates formation of sulfur hexafluoride lipid microspheres. 7.
• For preparation of doses greater than or equal to 1 mL, invert the system and slowly withdraw the intended volume of suspension into the syringe (see Figure 7).
• For preparation of doses less than 1 mL, withdraw 2 mL of the reconstituted suspension into the 5 mL syringe and measure the volume of Lumason to inject by using the 0.2 mL graduations between the 1 mL and 2 mL marks. 8.
• Unscrew the syringe from the Mini-Spike (see Figure 8).
• Peel and remove the diluent label to display the reconstituted product label.
• For intravenous administration, immediately connect the syringe to a dose administration line (20 G) and administer as directed under the Administration Instructions below.
• For intravesical administration, immediately connect the syringe to a sterile urinary catheter (6 French to 8 French) and administer as directed under the Administration Instructions below.
• Following reconstitution, Lumason suspension contains 1.5 to 5.6 x10 8 microspheres/mL with 45 mcg/mL of sulfur hexafluoride.
• Use immediately after reconstitution.
• If the suspension is not used immediately after reconstitution, resuspend the microspheres for a few seconds by hand agitation before the suspension is drawn into the syringe.
• Reconstituted suspension within a vial may be used for up to 3 hours from the time of its reconstitution.
• Maintain the vial containing the reconstituted suspension at room temperature 25°C (77°F); excursions permitted to 15° to 30°C (59° to 86°F). glass-vial-spike-syringe-and-rod figure 1 figure 2 figure 3 figure 4 figure 5 figure 6 figure 7 figure 8 2.3.2 Lumason Pack (20-vial pack) Contents of Lumason Pack *Please note:
• This presentation does not include pre-filled syringes of 0.9% Sodium Chloride Injection, USP (Diluent).
• Lumason vials are to be used with the supplied Mini-Spike only.
• Use only additive-free 0.9% Sodium Chloride Injection, USP for the reconstitution of Lumason.
• Reconstitution Inspect the Lumason components for signs of damage.
• Do not use the Lumason vial if the protective cap on the vial is not intact or other components in the pack show signs of damage.
• Use aseptic conditions for the preparation and administration of Lumason. 1.
• Obtain a 5 mL syringe, with luer lock tip, and fill with 5 mL of additive-free 0.9% Sodium Chloride Injection, USP (diluent) (see Figure 1).
• Two healthcare professionals (HCPs) should verify that the solution selected for reconstitution of Lumason is additive-free 0.9% Sodium Chloride Injection, USP.
• Ensure that any air in the syringe is expelled. [Note:
• A prefilled syringe containing additive-free 0.9% Sodium Chloride Injection, USP may be used.
• Ensure that any air in the syringe is expelled.] 2.
• Remove the Mini-Spike green cap and connect the syringe to the Mini-Spike by screwing it in clockwise (see Figure 2). 3.
• Remove the Mini-Spike spike protection and position the spike in the center of the rubber stopper of the vial.
• Press firmly inward until the spike is fully inserted in the stopper (see Figure 3). 4.
• Empty the entire 5 mL content of the syringe into the vial by pushing on the plunger rod (see Figure 4). 5.
• Shake vigorously for 20 seconds, mixing all the contents in the vial (see Figure 5).
• A homogeneous white milky liquid indicates formation of sulfur hexafluoride lipid microspheres. 6.
• To obtain required dose, invert the system and slowly withdraw the intended volume of suspension into the syringe (see Figure 6). 7.
• Unscrew the syringe from the Mini-Spike (see Figure 7). 8.
• Label the syringe using the peel-off sticker provided. 9.
• For intravenous administration, immediately connect the syringe to a dose administration line (20G) and administer as directed under the Administration Instructions below.
• For intravesical administration, immediately connect the syringe to a sterile urinary catheter (6 French to 8 French) and administer as directed under the Administration Instructions below.
• Following reconstitution, Lumason suspension contains 1.5 to 5.6 x10 8 microspheres/mL with 45 mcg/mL of sulfur hexafluoride.
• Use immediately after reconstitution.
• If the suspension is not used immediately after reconstitution, resuspend the microspheres for a few seconds by hand agitation before the suspension is drawn into the syringe.
• Reconstituted suspension within a vial may be used for up to 3 hours from the time of its reconstitution.
• Maintain the vial containing the reconstituted suspension at room temperature 25°C (77°F); excursions permitted to 15° to 30°C (59° to 86°F). glass vial spike labels figure figure 1 figure 2 figure 3 figure 4 figure 5 figure 6 figure 7
• 2.4 Administration Instructions Inspect visually for particulate matter and discoloration prior to administration, whenever solution and container permit.
• The reconstituted suspension is milky-white, and does not contain visible particulate matter.
• Do not use the single-patient use vial for more than one patient.
• Intravenous Administration Administer Lumason as an intravenous bolus injection.
• Intravesical Administration in Pediatric Patients Insert a sterile 6 French to 8 French urinary catheter into the bladder under sterile conditions;
• Empty the bladder of urine, and then fill the bladder with sterile 0.9% Sodium Chloride Injection, USP to approximately one third or half of its predicted total volume.
• The total bladder volume in children is calculated as [(age in years + 2) x 30] mL;
• Administer Lumason as an intravesical bolus injection through the urinary catheter;
• Continue filling the bladder with 0.9% Sodium Chloride Injection, USP until the patient has the urge to micturate or at the first sign of back pressure to the infusion.
• Immediately following the first voiding, the bladder may be refilled with 0.9% Sodium Chloride Injection, USP for a second cycle of voiding and imaging, without the need of a second Lumason administration.
• 2.5 Imaging Guidelines Echocardiography After baseline non-contrast echocardiography is complete, adjust the mechanical index for the ultrasound device to 0.8 or lower.
• Continue ultrasound imaging following Lumason injection.
• Ultrasonography of the Liver After identification of the target focal lesion on non-contrast ultrasound examination, hold transducer still while switching scanner to low mechanical index (≤ 0.4) contrast-specific imaging.
• Continue ultrasound imaging following Lumason injection.
• Ultrasonography of the Urinary Tract After baseline non-contrast ultrasound examination of the kidney and bladder, switch the scanner to low mechanical index (≤0.4) contrast specific imaging.
• Perform continuous alternate ultrasound imaging of the bladder, ureters, and kidneys during filling and voiding of the bladder.

Quoted from the official label, section “Dosage & Administration”.

Other warnings

Quoted from the official label, section “Warnings”.

Pregnancy and breastfeeding

Quoted from the official label, section “OTC — Pregnancy or Breast Feeding”.

Use in children

• Echocardiography Safety and effectiveness have been established for use in pediatric patients with suboptimal echocardiograms to opacify the left ventricular chamber and to improve delineation of the left endocardial border.
• Safety and effectiveness in pediatric patients are based on adequate and well-controlled studies in
• adults and are supported by a clinical study in 12 pediatric patients (mean age:
• 13.8 years) with extrapolation of efficacy to younger pediatric patients.
• No new adverse reactions were reported in the pediatric study [see Adverse Reactions ( 6.1 ) and Clinical Studies ( 14.1 )] .
• Safety of intravenous use of Lumason was based on evaluation of published literature involving the use of Lumason in over 1400 pediatric patients (0 to 17 years).
• Ultrasonography of the Liver Safety and effectiveness in pediatric patients has been established for use in ultrasonography of the liver for characterization of focal liver lesions from adequate and well controlled trials in adult patients and a clinical study of 44 pediatric patients [see Clinical Studies ( 14 )] .
• Safety of intravenous use of Lumason was based on evaluation of published literature involving use of Lumason in over 1400 pediatric patients.
• Non-fatal anaphylaxis was reported in one pediatric patient.
• Ultrasonography of the Urinary Tract Safety and effectiveness in pediatric patients has been established for use in ultrasonography of the urinary tract for the evaluation of suspected or known vesicoureteral reflux from two published studies comprising a total of 411 pediatric patients [see Clinical Studies ( 14 )] .
• Safety of intravesical use of Lumason was based on evaluation of published literature involving use of Lumason in over 6000 pediatric patients.
• No adverse reactions were reported.

Quoted from the official label, section “Pediatric Use”.

Use in older people

• Of the total number of 6856 adult patients in clinical studies of Lumason, 39% were 65 and over, while 11% were 75 and older.
• No overall differences in safety or effectiveness were observed between these subjects and younger subjects, and other reported clinical experience has not identified differences in responses between the elderly or younger patients, but greater sensitivity of some older individuals cannot be ruled out.

Quoted from the official label, section “Geriatric Use”.

Side effects

• The following serious adverse reactions are discussed elsewhere in the labeling:
• Cardiopulmonary reactions [see Warnings and Precautions ( 5.1 )] Hypersensitivity reactions [see Warnings and Precautions ( 5.2 )] Most common adverse reactions (incidence ≥ 0.5%) are headache and nausea ( 6.1 ).
• To report SUSPECTED ADVERSE REACTIONS, contact Bracco Diagnostics Inc at 1-800-257-5181 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch
• 6.1 Clinical Trials Experience Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.
• Adults In completed clinical trials, a total of 6984 adult subjects (128 healthy volunteers and 6856 patients) received Lumason at cumulative doses ranging from 0.2 to 161 mL (mean 9.8 mL).
• Lumason was administered mainly as single or multiple injections; however, some subjects received infusion dosing.
• The majority (75%) of subjects received Lumason at cumulative doses of 10 mL or less.
• There were 64% men and 36% women, with an average age of 59 years (range 17 to 99 years).
• A total of 79% subjects were White; 4% were Black; 16% were Asian; <1% were Hispanic; and <1% were in other racial groups or race was not reported.
• In the clinical trials, serious adverse reactions were observed in 2 subjects; one who experienced a hypersensitivity-type rash and presyncope and another who experienced anaphylactic shock shortly following Lumason administration.
• The most commonly reported adverse reactions among patients (occurring among at least 0.2% of patients) are listed below (Table 1).
• Most adverse reactions were mild to moderate in intensity and resolved spontaneously. *occurring in at least 0.2% of patients Table 1.
• Adverse Reactions in Adult Patients* n = 6856 Number (%) of Patients with Adverse Reactions 340 (5%) Headache 65 (1%) Nausea 37 (0.5%) Dysgeusia 29 (0.4%) Injection site pain 23 (0.3%) Feeling Hot 18 (0.3%) Chest discomfort 17 (0.2%) Chest pain 12 (0.2%) Dizziness 11 (0.2%) Injection Site Warmth 11 (0.2%) Pediatric Patients:
• In completed clinical trials for echocardiography, a total of 12 pediatric patients received Lumason at a dose of 0.03 mL/kg.
• No adverse reactions were identified in pediatric patients [see Clinical Studies ( 14.1 )] .
• 6.2 Postmarketing Experience In the international postmarketing clinical experience and clinical trials, serious adverse reactions have uncommonly been reported following administration of Lumason.
• Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure.
• The serious adverse reactions include fatalities, especially in a pattern of symptoms suggestive of anaphylactoid/hypersensitivity reactions.
• Other serious reactions included arrhythmias and hypertensive episodes.
• These reactions typically occurred within 30 minutes of Lumason administration.
• These serious reactions may be increased among patients with pre-existing PEG hypersensitivity and/or unstable cardiopulmonary conditions (acute myocardial infarction, acute coronary artery syndromes, worsening or unstable congestive heart failure, or serious ventricular arrhythmias) [see Warnings and Precautions ( 5.1 , 5.2 )] .
• Hypersensitivity Anaphylaxis, with manifestations that may include death, shock, bronchospasm, dyspnea, throat tightness, angioedema, edema (pharyngeal, palatal, mouth, peripheral, localized), swelling (face, eye, lip, tongue, upper airway), facial hypoesthesia, rash, urticaria, pruritus, flushing, and erythema.

Quoted from the official label, section “Adverse Reactions”.

What to discuss with your doctor

• Advise patients to inform their healthcare provider if they develop any symptoms of hypersensitivity after LUMASON administration including rash, wheezing, or shortness of breath.
• Manufactured for: Bracco Diagnostics Inc.
• Princeton, NJ 08540 by BRACCO Suisse SA Plan-les-Ouates Geneve, Switzerland (Lumason lyophilized powder vial-25 mg lipid- type A/60.7 mg sulfur hexafluoride gas) Vetter Pharma-Fertigung GmbH & Co.
• KG 88212 Ravensburg, Germany (0.9% Sodium Chloride Injection, USP) or Bracco Imaging S.p.A.
• Via Ribes, 5, 10010 Colleretto Giacosa (TO), Italy (0.9% Sodium Chloride Injection, USP) B.
• Braun Melsungen AG 34212 Melsungen, Germany (Mini-Spike) This product is covered by US Patent No. 5,686,060 Novaplus is a registered trademark of Vizient, Inc.
• CL1082-08 Revised: July 2024 novaplus logo

Quoted from the official label, section “Patient Counseling Information”.

Strengths and forms

• FORMS AND STRENGTHS For injectable suspension:
• Lumason is supplied in two presentations (single patient use kit or 20-vial pack):
• 3-part single patient use kit comprised of:
• one Lumason clear vial containing 25 mg of lipid-type A sterile white lyophilized powder with headspace filled with 60.7 mg of sulfur hexafluoride gas one prefilled syringe containing 5 mL of 0.9% Sodium Chloride Injection, USP (Diluent) one Mini-Spike 20-vial pack comprised of:
• twenty Lumason clear vials, each containing 25 mg of lipid-type A sterile white lyophilized powder with headspace filled with 60.7 mg of sulfur hexafluoride gas twenty Mini-Spikes twenty peel-off syringe labels Following reconstitution, Lumason is a homogeneous, milky white suspension containing 1.5 to 5.6 x 10 8 microspheres/mL with 45 mcg/mL of sulfur hexafluoride.
• For injectable suspension:
• 25 mg of lipid-type A lyophilized powder with headspace fill of 60.7 mg sulfur hexafluoride in a single-patient use vial for reconstitution ( 3 )

Quoted from the official label, section “Dosage Forms & Strengths”.

What it looks like and how it is packed

• 16.1 How Supplied Lumason (sulfur hexafluoride lipid-type A microspheres) for injectable suspension is supplied as a single patient use kit and as a 20-vial pack as follows:
• 5 single patient use kits (NDC 0270-7099-73) with each kit containing:
• One Lumason vial of 25 mg lipid-type A white lyophilized powder with headspace fill of 60.7 mg of sulfur hexafluoride One prefilled syringe containing 5mL of 0.9% Sodium Chloride Injection, USP (Diluent) One Mini-Spike Each kit is packaged in a clear plastic container. 20-vial pack (NDC 0270-7097-08) containing:
• Twenty (20) Lumason vials of 25 mg lipid-type A white lyophilized powder with headspace fill of 60.7 mg of sulfur hexafluoride Twenty (20) Mini-Spikes Twenty (20) peel-off syringe labels
• 16.2 Storage and Handling Store the kit at 25°C (77°F); excursions permitted to 15-30°C (59-86°F) [see USP Controlled Room Temperature].

Quoted from the official label, section “How Supplied”.

What is in it

• Lumason (sulfur hexafluoride lipid-type A microspheres) for injectable suspension, for intravenous or intravesical use is used to prepare the ultrasound contrast agent.
• Lumason is supplied in two presentations (single patient use kit or 20-vial pack):
• The single patient use kit contains the following three items:
• one clear glass 10 mL vial containing 25 mg of white lyophilized powder lipid-type A, 60.7 mg of sulfur hexafluoride gas and capped with a blue flip-cap one prefilled syringe containing 5 mL 0.9% Sodium Chloride Injection, USP (Diluent) Each prefilled syringe with 5 mL of diluent 0.9% Sodium Chloride Injection, USP is sterile, nonpyrogenic, and additive-free containing 9 mg sodium chloride per mL. one Mini-Spike The 20-vial pack is comprised of:
• twenty Lumason clear vials, each containing 25 mg of lipid-type A sterile white lyophilized powder with headspace filled with 60.7 mg of sulfur hexafluoride gas twenty Mini-Spikes twenty peel-off syringe labels Each vial is formulated as a 25 mg sterile, pyrogen-free lyophilized powder containing 24.56 mg of polyethylene glycol 4000, 0.19 mg of distearoylphosphatidyl-choline (DSPC), 0.19 mg of dipalmitoylphosphatidylglycerol sodium (DPPG-Na) and 0.04 mg of palmitic acid.
• The headspace of each vial contains 6.07 mg/mL (± 2 %) sulfur hexafluoride, SF 6 , or 60.7 mg per vial.
• Upon reconstitution with 5mL diluent, Lumason is a milky white, homogeneous suspension containing sulfur hexafluoride lipid-type A microspheres.
• The suspension is isotonic and has a pH of 4.5 to 7.5.
• The sulfur hexafluoride lipid microspheres are composed of SF 6 gas in the core surrounded by an outer shell monolayer of phospholipids consisting DSPC and DPPG-Na with palmitic acid as a stabilizer.
• Sulfur hexafluoride has a molecular weight of 145.9 and the following chemical structure:
• 1,2-Di s tearoyl- sn- glycero-3-phosphocholine (DSPC), with empirical formula C 44 H 88 NO 8 P, has a molecular weight of 790.6 and the following chemical structure:
• 1,2-Dipalmitoyl- sn -glycero-3-phospho- rac -glycerol sodium (DPPG-Na), with empirical formula C 38 H 74 NaO 10 P, has a molecular weight of 745 and the following chemical structure:
• Each milliliter of reconstituted Lumason suspension contains 1.5 to 5.6 x10 8 microspheres, 68 mcg SF 6 (12 mcL), 0.038 mg DSPC, 0.038 mg DPPG-Na, 4.91 mg polyethylene glycol 4000 and 0.008 mg palmitic acid.
• The sulphur hexafluoride associated with the microspheres suspension is 45 mcg/mL.
• Fifteen to twenty three percent of the total lipids in the suspension are associated with the microspheres.
• The sulfur hexafluoride lipid microsphere characteristics are listed in Table 2: Table 2.
• Microsphere Characteristics Mean diameter range 1.5 – 2.5 μm Percent of microspheres ≤ 10 µm ≥ 99% Upper size limit 100.0% ≤ 20 µm sulfur-hexafluoride-chemical-structure empirical-formula-790-6 empirical-formula-745

Quoted from the official label, section “Description”.

Ingredients people check for

Lactose, gluten, dyes, sugars and other ingredients that matter with an allergy, intolerance or diet — as this product’s FDA label lists them.

Same active substance, strength and form in other countries

Matched on active substance, strength and kind of form only. This is not a statement that the products are equivalent or interchangeable: other ingredients, release and approved uses can differ — ask a pharmacist before swapping.

Medicine passport: one printable page to show a pharmacist abroad

Details

Source: NDC Directory · 2026-09-13 · not reviewed by a clinician

Source: US Food and Drug Administration, NDC Directory. Reuse terms: US government work (FDA).

Report wrong or outdated information on this page

Other strengths and forms

2 products are sold under this name. Grouped by form; a number on a strength means several companies make it.

Same active substance

These contain the same substance. That does not mean one can replace another — ask a pharmacist.

See every product with Sulfur Hexafluoride